Novo Nordisk AS' and Sanofi's respective basal insulin/GLP-1 agonist fixed-ratio combination products, Xultophy and Soliqua, gained FDA approval Nov. 21 with narrower indications and different labeling than originally proposed.
Notably, the two drugs were approved the same day despite Sanofi's redemption of a priority review voucher that had
Novo's Xultophy 100/3.6, formerly referred to as iDegLira, is a fixed-dose combination of Tresiba (insulin degludec) and Victoza (liraglutide), a GLP-1 agonist. It has been marketed in the EU and Switzerland since January 2015